Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome
- PMID: 12657457
- DOI: 10.1016/s0168-0102(03)00005-1
Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome
Abstract
Individuals with Down's syndrome (DS) develop the pathological hallmarks of Alzheimer's (AD) disease at an early age, subsequently followed by memory decline and dementia. We have utilized an animal model for DS, mice with segmental trisomy of chromosome 16 (Ts65Dn), to study biological events linked to memory loss. Previous studies demonstrated a cognitive decline and loss of cholinergic markers after 6-8 months of age. In the current study, we found increased levels of amyloid precursor protein (APP) in the striatum by 6-8 months of age, and in the hippocampus and parietal cortex by 13-16 months of age in Ts65Dn but not in normosomic mice. Additionally, Ts65Dn mice exhibited alterations in nerve growth factor (NGF) levels in the basal forebrain and hippocampus. Ts65Dn mice demonstrated a significant decline in NGF levels in the basal forebrain with age, as well as a reduction in hippocampal NGF by 13-16 months of age. These findings demonstrate that elevated APP and decreased NGF levels in limbic areas correlate with the progressive memory decline and cholinergic degeneration seen in middle-aged trisomic mice.
Similar articles
-
Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.Neuron. 2006 Jul 6;51(1):29-42. doi: 10.1016/j.neuron.2006.05.022. Neuron. 2006. PMID: 16815330
-
Abnormal APP, cholinergic and cognitive function in Ts65Dn Down's model mice.Exp Neurol. 2005 Jun;193(2):469-80. doi: 10.1016/j.expneurol.2004.11.017. Exp Neurol. 2005. PMID: 15869949
-
Nerve growth factor metabolic dysfunction in Down's syndrome brains.Brain. 2014 Mar;137(Pt 3):860-72. doi: 10.1093/brain/awt372. Epub 2014 Feb 11. Brain. 2014. PMID: 24519975 Free PMC article.
-
Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome.Trends Pharmacol Sci. 2014 Jul;35(7):338-48. doi: 10.1016/j.tips.2014.04.010. Epub 2014 Jun 21. Trends Pharmacol Sci. 2014. PMID: 24962069 Review.
-
Neurotrophins and dementia--keeping in touch.Neuron. 2006 Jul 6;51(1):1-3. doi: 10.1016/j.neuron.2006.06.019. Neuron. 2006. PMID: 16815323 Review.
Cited by
-
Designer receptors enhance memory in a mouse model of Down syndrome.J Neurosci. 2015 Jan 28;35(4):1343-53. doi: 10.1523/JNEUROSCI.2658-14.2015. J Neurosci. 2015. PMID: 25632113 Free PMC article.
-
Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.Genes (Basel). 2021 Nov 20;12(11):1833. doi: 10.3390/genes12111833. Genes (Basel). 2021. PMID: 34828439 Free PMC article. Review.
-
Basal forebrain cholinergic neurons are vulnerable in a mouse model of Down syndrome and their molecular fingerprint is rescued by maternal choline supplementation.FASEB J. 2023 Jun;37(6):e22944. doi: 10.1096/fj.202202111RR. FASEB J. 2023. PMID: 37191946 Free PMC article.
-
Live imaging of neuronal connections by magnetic resonance: Robust transport in the hippocampal-septal memory circuit in a mouse model of Down syndrome.Neuroimage. 2007 Aug 1;37(1):230-42. doi: 10.1016/j.neuroimage.2007.05.010. Epub 2007 May 18. Neuroimage. 2007. PMID: 17566763 Free PMC article.
-
ERK-mediated NGF signaling in the rat septo-hippocampal pathway diminishes with age.Psychopharmacology (Berl). 2006 Nov;188(4):605-18. doi: 10.1007/s00213-006-0477-1. Epub 2006 Aug 17. Psychopharmacology (Berl). 2006. PMID: 16915384
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases